NGL Fine-Chem Limited announced its investor presentation for the quarter and year ended March 31, 2025.
The operating environment in Q4 FY25 remained challenging due to subdued demand and increased competition.
Geopolitical tensions between India and Pakistan impacted business in that region.
Phase 1 of the CAPEX project, including a clean room, has been commercialized, with validation batches underway.
Phase 2 of the CAPEX is expected to be completed by Q3 of the current financial year, with a total outlay estimated at approximately ₹160 crore, financed through a 60:40 debt-equity structure; meaningful contributions are expected from FY27 onwards.
Diversification into regulated markets remains a strategic priority.
Segmental Revenue Mix (FY25):
Animal API: 83%
Human API: 5%
Intermediates: 7%
Formulations: 5%
Geographic Mix (FY25):
Asia: 34%
Europe: 30%
India: 22%
ROW: 12%
USA: 2%
Customer Concentration (FY25):
Top 3 Customers: 17%
Top 5 Customers: 24%
Top 10 Customers: 35%
Summary of Profit and Loss Statement (₹ in Crores):
Revenue from Operations: ₹368.68 crore (FY25) vs ₹338.26 crore (YoY 8.73%)
Total Income: ₹352.81 crore
EBITDA: ₹33.87 crore
Profit After Tax: ₹21.12 crore
Management Commentary: The operating environment in Q4 FY25 remained challenging. Uncertainty persists regarding the duration of this downcycle. Despite these headwinds, we are pleased to report the successful commercialisation of Phase 1 of our CAPEX project during the quarter.